Sage Therapeutics (SAGE) News Today

The Goldman Sachs Group reduced their price target on shares of Sage Therapeutics from $19.00 to $11.00 and set a "neutral" rating on the stock in a research report on Friday.

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Sage Therapeutics in a research note issued on Wednesday, July 24th. Wedbush analyst L. Chico anticipates that the biopharmaceutical company will earn ($1.75) per share for

Scotiabank decreased their price target on shares of Sage Therapeutics from $19.00 to $17.00 and set a "sector outperform" rating on the stock in a research note on Thursday.

Sage Therapeutics (NASDAQ:SAGE) Hits New 52-Week Low on Analyst Downgrade

HC Wainwright reissued a "neutral" rating and issued a $25.00 price objective on shares of Sage Therapeutics in a research report on Thursday.

JPMorgan Chase & Co. cut Sage Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the company from $18.00 to $12.00 in a research note on Thursday.

Sage Therapeutics (NASDAQ:SAGE) Shares Gap Down to $13.08

Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday.

Sage Therapeutics (NASDAQ:SAGE) will be releasing earnings after the market closes on Wednesday, July 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=609421)

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has earned a consensus rating of "Hold" from the twenty ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and three have

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) was the recipient of a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 5,670,000 shares, a decline of 27.3% from the June 15th total of 7,800,000 shares. Approximately 11.5% of the shares of the company are sold short. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is currently 4.4 days.

BNP Paribas Financial Markets lessened its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 41.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 197,089 shares of the biopharmaceutical company's stock after selling 139

Sage Therapeutics (NASDAQ:SAGE) Shares Up 3.5%

Vanguard Group Inc. raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 2.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,319,360 shares of the biopharmaceutical company's stock after

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty analysts that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, fifteen have given a hold recommend

Sage Therapeutics (NASDAQ:SAGE) Shares Down 4.4%

Wellington Management Group LLP lowered its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,061,996 shares of the biopharmaceutical company's stock

JPMorgan Chase & Co. cut their price target on Sage Therapeutics from $28.00 to $23.00 and set an "overweight" rating for the company in a report on Thursday.

Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 1,049.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 201,107 shares of the biopharmaceutical company's stock after acqui

Sage Therapeutics (NASDAQ:SAGE) Shares Down 5.4%

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) was the target of a large decline in short interest in May. As of May 31st, there was short interest totalling 6,950,000 shares, a decline of 17.8% from the May 15th total of 8,460,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently 6.0 days. Approximately 14.0% of the shares of the stock are short sold.

Sage Therapeutics (NASDAQ:SAGE) Trading Up 5.4%

Sage Therapeutics (NASDAQ:SAGE) Sees Large Volume Increase

Sage Therapeutics (NASDAQ:SAGE) Sets New 12-Month Low at $10.19

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at Wedbush lifted their Q2 2024 EPS estimates for Sage Therapeutics in a research note issued to investors on Thursday, June 6th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings

Rafferty Asset Management LLC decreased its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 25.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,914 shares of the biopharmaceutical company's sto